Biomedical Research

Objective: This study was aimed to explore the impact of Endostar bolus infusion combined with chemotherapy on serum VEGF, circulating endothelial cells and endostatin levels of patients with Small Cell Lung Cancer (SCLC).

Methods: In our hospital, from January 2011 to December 2014, 30 cases pathologically diagnosed as malignant patients of III and IV stages were randomly divided into chemotherapy group (Group A), endostar conventional infusion combined with chemotherapy group (Group B) and endostar bolus and sequential continuous infusion combined with chemotherapy group (Group C) in each group with 10 patients who were respectively given the treatment of chemotherapy, Endostar conventional combination chemotherapy infusion and endostar bolus and sequential continuous infusion in combination with chemotherapy. Serum VEGF, circulating endothelial cells and endostatin levels of the patients were detected by ELISA before and after treatment.

Results: After 4 w of treatment, the endostatin of patients increased while VEGF and circulating endothelial cells decreased in group C, but the difference was not statistically significant (P>0.05) compared with groups A and B. 8 and 12 w after treatment, the endostatin of patients in group C increased significantly while VEGF and circulating endothelial cells strikingly decreased, and compared with groups A and B, the difference was statistically significant (P<0.05).

Conclusion: This study revealed the changing regularity of VEGF, circulating endothelial cells and endostatin levels of patients with the treatment of endostar bolus infusion combined with chemotherapy. After treatment, the serum endostatin of patients significantly increased while VEGF and circulating endothelial cells significantly decreased, suggesting that endostar bolus infusion combined with chemotherapy has direct inhibitory effect on neovascularization of SCLC tumor tissues.

Author(s): Dejun Gao, Wei Song, Jianliang Li
Abstract | Full-Text | PDF

Share this